2024 Annual Meeting | Industry Therapeutic Update from UCB: Harnessing New Potential in Generalized Myasthenia Gravis (gMG): When Individuality Meets Optionality

Date Monday 04/15/24

Time 11:45 AM - 12:45 PM MDT Add To Calendar

Location Colorado Convention Center | Bluebird 3A

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Neelam Goyal, MD

Topic(s) General Neurology, Autoimmune Neurology

Learning Objectives Join UCB and renowned generalized myasthenia gravis (gMG) experts at this interactive lunch symposium as we discuss the importance of shared decision-making approaches within an era of new targeted therapies that harness the potential of gMG care. Through exploration of data and real-world patient cases, this session will reveal clinicians’ perspectives on how to balance the individuality of each patient and the optionality of treatment within your clinical practice. Don’t miss this opportunity to attend this important and timely program as we look to bring our patient and HCP communities together.
This program will aim to meet the following objectives:

Explore evidence-based and practical considerations to facilitate clinical and patient preference-driven treatment decisions in an era of new gMG targeted therapies
Highlight the importance of optionality in gMG care to support the unique needs of each patient's lived experience
Share clinician perspectives on the practical application of shared decision-making and goal setting in practice

This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM MDT	Speaker	Industry Therapeutic Update from UCB: Harnessing New Potential in Generalized Myasthenia Gravis (gMG): When Individuality Meets Optionality

Faculty Disclosures
Neelam Goyal, MD	Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Goyal has received research support from Argenx.